Currently, therapeutic decisions for ICI—regimens in stage IV NSCLC are based on immunohistochemistry (IHC) analyses of PD‐L1 expression in surgical specimens or on core needle biopsies (CNB) and in certain cases, with immunocytochemistry (ICC) of FNAs [7, 8, 9, 10, 11, 12]. This evidence concerns the gene CD274 and intrahepatic cholangiocarcinoma.